162 related articles for article (PubMed ID: 17437111)
1. Kinetics of CXCR-4 and adhesion molecule expression during autologous stem cell mobilisation with G-CSF plus AMD3100 in patients with multiple myeloma.
Oelschlaegel U; Bornhauser M; Boxberger S; Kroschinsky F; Illmer T; Hoelig K; Calandra G; Ehninger G; Platzbecker U
Ann Hematol; 2007 Aug; 86(8):569-73. PubMed ID: 17437111
[TBL] [Abstract][Full Text] [Related]
2. Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial.
Nademanee AP; DiPersio JF; Maziarz RT; Stadtmauer EA; Micallef IN; Stiff PJ; Hsu FJ; Bridger G; Bolwell BJ
Biol Blood Marrow Transplant; 2012 Oct; 18(10):1564-72. PubMed ID: 22683613
[TBL] [Abstract][Full Text] [Related]
3. AMD3100 mobilizes hematopoietic stem cells with long-term repopulating capacity in nonhuman primates.
Larochelle A; Krouse A; Metzger M; Orlic D; Donahue RE; Fricker S; Bridger G; Dunbar CE; Hematti P
Blood; 2006 May; 107(9):3772-8. PubMed ID: 16439684
[TBL] [Abstract][Full Text] [Related]
4. Plerixafor: A chemokine receptor-4 antagonist for mobilization of hematopoietic stem cells for transplantation after high-dose chemotherapy for non-Hodgkin's lymphoma or multiple myeloma.
Steinberg M; Silva M
Clin Ther; 2010 May; 32(5):821-43. PubMed ID: 20685493
[TBL] [Abstract][Full Text] [Related]
5. Role of CXCR4 chemokine receptor blockade using AMD3100 for mobilization of autologous hematopoietic progenitor cells.
Flomenberg N; DiPersio J; Calandra G
Acta Haematol; 2005; 114(4):198-205. PubMed ID: 16269859
[TBL] [Abstract][Full Text] [Related]
6. Dual stem cell therapy after myocardial infarction acts specifically by enhanced homing via the SDF-1/CXCR4 axis.
Theiss HD; Vallaster M; Rischpler C; Krieg L; Zaruba MM; Brunner S; Vanchev Y; Fischer R; Gröbner M; Huber B; Wollenweber T; Assmann G; Mueller-Hoecker J; Hacker M; Franz WM
Stem Cell Res; 2011 Nov; 7(3):244-55. PubMed ID: 21752744
[TBL] [Abstract][Full Text] [Related]
7. Plerixafor, a CXCR4 antagonist for the mobilization of hematopoietic stem cells.
Uy GL; Rettig MP; Cashen AF
Expert Opin Biol Ther; 2008 Nov; 8(11):1797-804. PubMed ID: 18847313
[TBL] [Abstract][Full Text] [Related]
8. Durable engraftment of AMD3100-mobilized autologous and allogeneic peripheral-blood mononuclear cells in a canine transplantation model.
Burroughs L; Mielcarek M; Little MT; Bridger G; Macfarland R; Fricker S; Labrecque J; Sandmaier BM; Storb R
Blood; 2005 Dec; 106(12):4002-8. PubMed ID: 16105977
[TBL] [Abstract][Full Text] [Related]
9. G-CSF administration favours SDF-1 release and activation of neutrophils and monocytes in recipients of autologous peripheral blood progenitor cells.
Gębura K; Butrym A; Chaszczewska-Markowska M; Wróbel T; Kuliczkowski K; Bogunia-Kubik K
Cytokine; 2019 Apr; 116():38-47. PubMed ID: 30685602
[TBL] [Abstract][Full Text] [Related]
10. [In vivo effect of rhG-CSF on the CXCR-4 expression of hematopoietic progenitor or stem cells in bone marrow and peripheral blood].
Zhao XY; Chang YJ; Huang XJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Oct; 13(5):857-60. PubMed ID: 16277858
[TBL] [Abstract][Full Text] [Related]
11. The CXCR4 antagonist AMD3100 releases a subset of G-CSF-primed peripheral blood progenitor cells with specific gene expression characteristics.
Fruehauf S; Seeger T; Maier P; Li L; Weinhardt S; Laufs S; Wagner W; Eckstein V; Bridger G; Calandra G; Wenz F; Zeller WJ; Goldschmidt H; Ho AD
Exp Hematol; 2006 Aug; 34(8):1052-9. PubMed ID: 16863911
[TBL] [Abstract][Full Text] [Related]
12. The AMD3100 story: the path to the discovery of a stem cell mobilizer (Mozobil).
De Clercq E
Biochem Pharmacol; 2009 Jun; 77(11):1655-64. PubMed ID: 19161986
[TBL] [Abstract][Full Text] [Related]
13. The high-affinity CXCR4 antagonist BKT140 is safe and induces a robust mobilization of human CD34+ cells in patients with multiple myeloma.
Peled A; Abraham M; Avivi I; Rowe JM; Beider K; Wald H; Tiomkin L; Ribakovsky L; Riback Y; Ramati Y; Aviel S; Galun E; Shaw HL; Eizenberg O; Hardan I; Shimoni A; Nagler A
Clin Cancer Res; 2014 Jan; 20(2):469-79. PubMed ID: 24246358
[TBL] [Abstract][Full Text] [Related]
14. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist.
Broxmeyer HE; Orschell CM; Clapp DW; Hangoc G; Cooper S; Plett PA; Liles WC; Li X; Graham-Evans B; Campbell TB; Calandra G; Bridger G; Dale DC; Srour EF
J Exp Med; 2005 Apr; 201(8):1307-18. PubMed ID: 15837815
[TBL] [Abstract][Full Text] [Related]
15. Update on clinical experience with AMD3100, an SDF-1/CXCL12-CXCR4 inhibitor, in mobilization of hematopoietic stem and progenitor cells.
Pusic I; DiPersio JF
Curr Opin Hematol; 2010 Jul; 17(4):319-26. PubMed ID: 20473162
[TBL] [Abstract][Full Text] [Related]
16. Plerixafor (Mozobil) alone to mobilize hematopoietic stem cells from multiple myeloma patients for autologous transplantation.
Flomenberg N; Comenzo RL; Badel K; Calandra G
Biol Blood Marrow Transplant; 2010 May; 16(5):695-700. PubMed ID: 20067838
[TBL] [Abstract][Full Text] [Related]
17. In and out of the niche: perspectives in mobilization of hematopoietic stem cells.
Mohty M; Ho AD
Exp Hematol; 2011 Jul; 39(7):723-9. PubMed ID: 21624427
[TBL] [Abstract][Full Text] [Related]
18. Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction.
Devine SM; Vij R; Rettig M; Todt L; McGlauchlen K; Fisher N; Devine H; Link DC; Calandra G; Bridger G; Westervelt P; Dipersio JF
Blood; 2008 Aug; 112(4):990-8. PubMed ID: 18426988
[TBL] [Abstract][Full Text] [Related]
19. Recent advances on the use of the CXCR4 antagonist plerixafor (AMD3100, Mozobil™) and potential of other CXCR4 antagonists as stem cell mobilizers.
De Clercq E
Pharmacol Ther; 2010 Dec; 128(3):509-18. PubMed ID: 20826182
[TBL] [Abstract][Full Text] [Related]
20. Improved mobilization of peripheral blood CD34+ cells and dendritic cells by AMD3100 plus granulocyte-colony-stimulating factor in non-Hodgkin's lymphoma patients.
Gazitt Y; Freytes CO; Akay C; Badel K; Calandra G
Stem Cells Dev; 2007 Aug; 16(4):657-66. PubMed ID: 17784839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
